Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Calcipotriene, betamethasone dipropionate

Drug class: Vitamin D Analog

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Calcipotriene, betamethasone dipropionate key facts

Drug class
Vitamin D Analog
Used for
Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$1.21–$1.45 per gram (betamethasone dipropionate 0.05% · calcipotriene 50 ug/g; NADAC)
Latest FDA recall
None listed

Sources: FDA label (April 30, 2024); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Calcipotriene, betamethasone dipropionate used for?
The FDA-approved label (Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd, April 30, 2024) says: “Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Calcipotriene and Betamethasone Dipropionate Ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Calcipotriene, betamethasone dipropionate?
The “Adverse Reactions” section of the FDA label (Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd, April 30, 2024) begins: “Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (≥1%) are pruritus and scaly rash.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Calcipotriene, betamethasone dipropionate have a boxed warning?
No. None of the 8 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Calcipotriene, betamethasone dipropionate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Calcipotriene, betamethasone dipropionate been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Calcipotriene, betamethasone dipropionate?
6 companies list prescription products of Calcipotriene, betamethasone dipropionate in the FDA NDC Directory, including Bryant Ranch Prepack, MC2 Therapeutics Ltd and Perfero Pharma, Inc.

What Calcipotriene, betamethasone dipropionate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Calcipotriene and Betamethasone Dipropionate Ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.

— FDA label: Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd, effective April 30, 2024. Read the full label on DailyMed →

Label quoted: the one for the most common form (ointment, topical), Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 8 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 8 FDA labels for this medicine have a boxed warning.

Calcipotriene, betamethasone dipropionate side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (≥1%) are pruritus and scaly rash.

Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Clinical Trials Conducted in Subjects 18 years and older with Plaque Psoriasis The data described below reflect exposure to calcipotriene and betamethasone dipropionate ointment in 2448 subjects with plaque psoriasis, including 1992 exposed for 4 weeks, and 289 exposed for 8 weeks. Calcipotriene and betamethasone dipropionate ointment was studied primarily in placebo- and active-controlled trials (N = 1176, and N = 1272, respectively). The population was 15-97 years old, 61% males and 39% females, mostly white (97%) and had a baseline disease severity ranging from mild to very severe. Most subjects received once daily application, and the median weekly dose was 24.5 g. The percentage of subjects reporting at least one adverse event was 27.1% in the calcipotriene and betamethasone dipropionate ointment group, 33.0% in the calcipotriene group, 28.3% in the betamethasone group, and 33.4% in the vehicle group. Table 1 Adverse Events Reported by ≥ 1% of Subjects by Preferred Term Calcipotriene and betamethasone dipropionate ointment N = 2448 Calcipotriene N = 3197 Betamethasone dipropionate N = 1164 Vehicle N = 470 Any Adverse Event 663 (27.1) 1055 (33.0) 329 (28.3) 157 (33.4) Preferred Term # of subjects (%) Pruritus 75 (3.1) 183 (5.7) 38 (3.3) 43 (9.1) Headache 69 (2.8) 75 (2.3) 44 (3.8) 12 (2.6) Nasopharyngitis 56 (2.3) 77 (2.4) 34 (2.9) 9 (1.9) Psoriasis 30 (1.2) 47 (1.5) 14 (1.2) 5 (1.1) Rash scaly 30 (1.2) 40 (1.3) 0 (0.0) 1 (0.2) Influenza 23 (0.9) 34 (1.1) 14 (1.2) 6 (1.3) Upper respiratory tract infection 20 (0.8) 19 (0.6) 12 (1.0) 3 (0.6) Erythema 15 (0.6) 54 (1.7) 3 (0.3) 5 (1.1) Application site pruritus 13 (0.5) 24 (0.8) 10 (0.9) 6 (1.3) Skin irritation 11 (0.4) 60 (1.9) 8 (0.7) 5 (1.1) Pain 7 (0.3) 12 (0.4) 3 (0.3) 5 (1.1) Burning sensation 6 (0.2) 30 (0.9) 3 (0.3) 6 (1.3) A lesional/perilesional adverse event was generally defined as an adverse event located ≤ 2 cm from the lesional border.

Table from the label
Calcipotriene and betamethasone dipropionate ointmentN = 2448CalcipotrieneN = 3197Betamethasone dipropionateN = 1164VehicleN = 470
Any Adverse Event213 (8.7)419 (13.1)85 (7.3)76 (16.2)
Preferred Term# of subjects (%)
Pruritus69 (2.8)170 (5.3)31 (2.7)41 (8.7)
Rash scaly29 (1.2)38 (1.2)0 (0.0)0 (0.0)
Application site pruritus12 (0.5)24 (0.8)10 (0.9)6 (1.3)
Erythema9 (0.4)36 (1.1)2 (0.2)4 (0.9)
Skin irritation9 (0.4)51 (1.6)8 (0.7)5 (1.1)
Burning sensation6 (0.2)25 (0.8)3 (0.3)5 (1.1)

— FDA label: Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd, effective April 30, 2024. This is part of the section. Read the full label on DailyMed →

Calcipotriene, betamethasone dipropionate dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Apply an adequate layer of Calcipotriene and Betamethasone Dipropionate Ointment to the affected area(s) once daily for up to 4 weeks. Calcipotriene and Betamethasone Dipropionate Ointment should be rubbed in gently and completely. Patients should wash their hands after applying Calcipotriene and Betamethasone Dipropionate Ointment. Therapy should be discontinued when control is achieved.

Read more of this section

Patients 18 years and older should not use more than 100 g per week and patients 12 to 17 years should not use more than 60 g per week. Treatment of more than 30% body surface area is not recommended. Calcipotriene and Betamethasone Dipropionate Ointment should not be used with occlusive dressings unless directed by a physician. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. Calcipotriene and Betamethasone Dipropionate Ointment is not for oral, ophthalmic, or intravaginal use.

  • Apply Calcipotriene and Betamethasone Dipropionate Ointment to affected area(s) once daily for up to 4 weeks. Discontinue therapy when control is achieved. (2)
  • Adult patients should not use more than 100 g per week. (2)
  • Patients ages 12 to 17 years should not use more than 60 g per week. (2)
  • Treatment of more than 30% body surface area is not recommended. (2)
  • Do not use with occlusive dressings unless directed by a physician. (2)
  • Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. (2)
  • Not for oral, ophthalmic, or intravaginal use. (2)

— FDA label: Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd, effective April 30, 2024. Read the full label on DailyMed →

Calcipotriene, betamethasone dipropionate in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Calcipotriene and Betamethasone Dipropionate Ointment contains calcipotriene and bethamethasone dipropionate. The limited data with Calcipotriene and Betamethasone Dipropionate Ointment and calcipotriene use in pregnant women are not sufficient to evaluate a Calcipotriene and Betamethasone Dipropionate Ointment-associated or calcipotriene-associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes.

Read more of this section

Observational studies suggest an increased risk of having low birthweight infants with the maternal use of potent or very potent topical corticosteroids (see Data). Advise pregnant women that Calcipotriene and Betamethasone Dipropionate Ointment may increase the potential risk of having a low birth weight infant and to use Calcipotriene and Betamethasone Dipropionate Ointment on the smallest area of skin and for the shortest duration possible. In animal reproduction studies, oral administration of calcipotriene to pregnant rats during the period of organogenesis resulted in an increased incidence of minor skeletal abnormalities, including enlarged fontanelles and extra ribs (see Data). Oral administration of calcipotriene to pregnant rabbits during the period of organogenesis had no apparent effects on embryo-fetal development. Subcutaneous administration of betamethasone dipropionate to pregnant rats and rabbits during the period of organogenesis resulted in fetal toxicity, including fetal deaths, reduced fetal weight, and fetal malformations (cleft palate and crooked or short tail) (see Data). The available data do not allow the calculation of relevant comparisons between the systemic exposures of calcipotriene and betamethasone diproprionate observed in animal studies to the systemic exposures that would be expected in humans after topical use of calcipotriene and betamethasone dipropionate ointment. The estimated background risk of major birth defects and miscarriage of the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Available observational studies in pregnant women did not identify a drug-associated risk of major birth defects, preterm delivery, or fetal mortality with the use of topical corticosteroids of any potency. However, when the dispensed amount of potent or very potent topical corticosteroids exceeded 300 g during the entire pregnancy, maternal use was associated with an increased risk of low birth weight in infants. Animal Data Embryo-fetal development studies with calcipotriene were performed by the oral route in rats and rabbits. Pregnant rats received dosages of 0, 6, 18, or 54 mcg/kg/day (0, 36, 108, and 324 mcg/m 2 /day, respectively) on days 6-15 of gestation (the period of organogenesis). There were no apparent effects on maternal survival, behavior, or body weight gain, no effects on litter parameters, and no effects on the incidence of major malformations in fetuses. Fetuses from dams dosed at 54 mcg/kg/day exhibited a significantly increased incidence of minor skeletal abnormalities, including enlarged fontanelles and extra ribs.

— FDA label: Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd, effective April 30, 2024. This is part of the section. Read the full label on DailyMed →

Calcipotriene, betamethasone dipropionate overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

Topically applied Calcipotriene and Betamethasone Dipropionate Ointment can be absorbed in sufficient amounts to produce systemic effects [see Warnings and Precautions (5.1, 5.2)].

— FDA label: Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd, effective April 30, 2024. Read the full label on DailyMed →

Forms and how it is given

Dosage formsOintment · Suspension · Cream · Solution
RouteTopical
Prescription products8 in the FDA NDC Directory
Brand namesWynzora, Attero

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Calcipotriene, betamethasone dipropionate, by strength and form
Strength and formGeneric or brandPharmacies pay
betamethasone dipropionate 0.05% · calcipotriene 50 ug/g
suspension
Generic $1.21–$1.45 per gram
2 packages, lowest to highest
betamethasone dipropionate 0.0643% · calcipotriene 50 ug/g
ointment
Generic $1.41–$2.14 per gram
2 packages, lowest to highest
betamethasone dipropionate 5% · calcipotriene 50 ug/g
suspension
Generic $1.21–$1.45 per gram
2 packages, lowest to highest

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA213422
WYNZORA
MC2July 20, 2020 —

Generic approvals (3)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)388525, 833461, 2471873, 2471878
SPL set ID of the quoted labelba55ff2b-9cfe-40dc-9dac-718cf141c171
FDA labels (SPL)8
FDA applicationsNDA213422, 3 ANDA
Active ingredients (FDA)BETAMETHASONE DIPROPIONATE / CALCIPOTRIENE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Calcipotriene and Betamethasone Dipropionate, Padagis Israel Pharmaceuticals Ltd, effective April 30, 2024; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers